News & Events

The U.S. Department of Defense Prostate Cancer Research Program has awarded $1.2 million to  University of Illinois Chicago (UIC) researchers who are part of the University of Illinois Cancer Center, the Retzky College of Pharmacy and the College of Medicine.

The three-year Data Science Award to Cancer Center members Charles Gaber, PhD, MPH, (Pharmacy) and Natalie Reizine, MD, (Medicine), and Pharmacy's Todd Lee, PharmD, PhD, will fund the project, "Leveraging Data Science Methods to Deliver Individualized Treatment Effects in Metastatic Hormone Sensitive Prostate Cancer," which also includes colleagues at Northwestern University and the Moffitt Cancer Center in Tampa, Florida. 

The project seeks to drive improvements in the effective use of androgen deprivation therapy (ADT) combination therapy in men diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) and determine how stringent eligibility criteria may limit the generalizability of trial findings. The objective will be achieved by using cutting-edge data science methods, including supervised machine learning, hybrid epidemiologic designs, and target trial emulation. The central tenet of the proposed work is that the additional benefits and risks of adding abiraterone or apalutamide to treatment with ADT are not uniform across men diagnosed with mHSPC.

The project will: develop and evaluate the impact of personalized treatment strategies from the LATITUDE and TITAN randomized controlled trials; determine the impact of broadening the eligibility criteria of LATITUDE and TITAN on trial eligibility in real-world populations; and estimate the effectiveness of combination therapy in real-world cohorts and characterize heterogeneous treatment effects.

Charles Gaber, PhD, MPH, Assistant Professor, Pharmacy Systems, Outcomes and Policy

Natalie Reizine, MD, Assistant Professor, Division of Hematology and Oncology/UI Health Medical Oncologist

Todd Lee, PharmD, PhD, Professor and Head, Pharmacy Systems, Outcomes and Policy